Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control

Oncogene

Volumn 30, Issue 32, 2011, Pages 3502-3512

  Jakel H ^a   Weinl, C ^a   Hengst, L ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

CDK inhibitors; cell cycle control; JAK2; JAK2V617F; p27Kip1; tyrosine kinases

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOKINE RECEPTOR; JANUS KINASE 2;

ALLELE; ARTICLE; CARCINOGENESIS; CELL CYCLE REGULATION; CELL LEVEL; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; ENZYME STABILITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ANIMALS; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPLASM; ENZYME ACTIVATION; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; INTERLEUKIN-3; JANUS KINASE 2; MICROSCOPY, CONFOCAL; MUTATION; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, CYTOKINE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; TYROSINE;

EID: 80051802413     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.68     Document Type: Article

References (41)

1. Agarwal A, Bumm TG, Corbin AS, O'Hare T, Loriaux M, VanDyke J et al. (2008). Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood 112:1960-1970.
2. Baker SJ, Rane SG, Reddy EP. (2007). Hematopoietic cytokine receptor signaling. Oncogene 26:6724-6737. (Pubitemid 47585098)
3. Behrmann I, Smyczek T, Heinrich PC, Schmitz-Van de Leur H, Komyod W, Giese B et al. (2004). Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase. J Biol Chem 279:35486-35493. (Pubitemid 39100548)
4. Bruchova H, Yoon D, Agarwal AM, Swierczek S, Prchal JT. (2009). Erythropoiesis in polycythemia vera is hyper-proliferative and has accelerated maturation. Blood Cells Mol Dis 43:81-87.
5. Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S et al. (2007). p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 128:281-294. (Pubitemid 46123510)
6. Chu IM, Hengst L, Slingerland JM. (2008). The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8:253-267. (Pubitemid 351430863)
7. Connor MK, Kotchetkov R, Cariou S, Resch A, Lupetti R, Beniston RG et al. (2003). CRM1/Ran-mediated nuclear export of p27 (Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell 14:201-213. (Pubitemid 36106030)
8. Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green AR et al. (2009). JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461:819-822.
9. Desrivieres S, Kunz C, Barash I, Vafaizadeh V, Borghouts C, Groner B. (2006). The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition. J Mammary Gland Biol Neoplasia 11:75-87. (Pubitemid 44309191)
10. Feng J, Witthuhn BA, Matsuda T, Kohlhuber F, Kerr IM, Ihle JN. (1997). Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 17:2497-2501. (Pubitemid 27175130)
11. Frescas D, Pagano M. (2008). Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8:438-449. (Pubitemid 351744963)
12. Furuhata A, Kimura A, Shide K, Shimoda K, Murakami M, Ito H et al. (2009). p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation. Biochem Biophys Res Commun 383:411-416.
13. Grimmler M, Wang Y, Mund T, Cilensek Z, Keidel EM, Waddell MB et al. (2007). Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 128:269-280. (Pubitemid 46123508)
14. Halfter H, Friedrich M, Resch A, Kullmann M, Stogbauer F, Ringelstein EB et al. (2006). Oncostatin M induces growth arrest by inhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression. Cancer Res 66:6530-6539. (Pubitemid 44085607)
15. Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI. (1994). A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA 91:5291-5295. (Pubitemid 24174312)
16. Hengst L, Reed SI. (1996). Translational control of p27Kip1 accumulation during the cell cycle. Science 271:1861-1864.
17. Ihle JN, Gilliland DG. (2007). Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 17:8-14. (Pubitemid 46109298)
18. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. (2005). A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148. (Pubitemid 40663494)
19. James MK, Ray A, Leznova D, Blain SW. (2008). Differential modification of p27Kip1 controls its cyclin D-cdk4 inhibitory activity. Mol Cell Biol 28:498-510.
20. Kardinal C, Dangers M, Kardinal A, Koch A, Brandt DT, Tamura T et al. (2006). Tyrosine phosphorylation modulates binding preference to cyclin-dependent kinases and subcellular localization of p27Kip1 in the acute promyelocytic leukemia cell line NB4. Blood 107:1133-1140. (Pubitemid 43156315)
21. Kelvin DJ, Chance S, Shreeve M, Axelrad AA, Connolly JA, McLeod D. (1986). Interleukin 3 and cell cycle progression. J Cell Physiol 127:403-409. (Pubitemid 16065391)
22. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. (2005). A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790. (Pubitemid 40570926)
23. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS et al. (1997). New functional activities for the p21 family of CDK inhibitors. Genes Dev 11:847-862. (Pubitemid 27175292)
24. Larrea MD, Liang J, Da Silva T, Hong F, Shao SH, Han K et al. (2008). Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4. Mol Cell Biol 28:6462-6472.
25. Levine RL, Gilliland DG. (2007). JAK-2 mutations and their relevance to myeloproliferative disease. Curr Opin Hematol 14:43-47. (Pubitemid 44885611)
26. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. (2005). Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397. (Pubitemid 40544655)
27. Malumbres M, Barbacid M. (2009). Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9:153-166.
28. Morgan DO. (1997). Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261-291. (Pubitemid 28034527)
29. Neilson LM, Zhu J, Xie J, Malabarba MG, Sakamoto K, Wagner KU et al. (2007). Coactivation of janus tyrosine kinase (Jak) 1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat) 3 and enhancement of Akt and Stat5a/b pathways. Mol Endocrinol 21:2218-2232. (Pubitemid 47347383)
30. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S et al. (1998). Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93:385-395. (Pubitemid 28232083)
31. Ray A, James MK, Larochelle S, Fisher RP, Blain SW. (2009). p27Kip1 inhibits cyclin D-cyclin-dependent kinase 4 by two independent modes. Mol Cell Biol 29:986-999.
32. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101. (Pubitemid 40262113)
33. Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, Cunningham BR et al. (2002). Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett 12:1219-1223. (Pubitemid 34270567)
34. Tossidou I, Dangers M, Koch A, Brandt DT, Schiffer M, Kardinal C. (2008). Tyrosine phosphatase SHP-2 is a regulator of p27 (Kip1) tyrosine phosphorylation. Cell Cycle 7:3858-3868.
35. Verstovsek S. (2009). Therapeutic potential of JAK2 inhibitors. Hematol Am Soc Hematol Educ Program, 636-642.
36. Wallace TA, Sayeski PP. (2006). Jak2 tyrosine kinase: a mediator of both housekeeping and ligand-dependent gene expression? Cell Biochem Biophys 44:213-222. (Pubitemid 43172319)
37. Walz C, Crowley BJ, Hudon HE, Gramlich JL, Neuberg DS, Podar K et al. (2006). Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem 281:18177-18183. (Pubitemid 44035617)
38. Wei W, Ayad NG, Wan Y, Zhang GJ, Kirschner MW, Kaelin Jr WG. (2004). Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature 428:194-198. (Pubitemid 38374317)
39. Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE et al. (2008). The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim protooncogenes. Blood 111:3751-3759.
40. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB et al. (2005). Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788-22792. (Pubitemid 40853184)
41. Zhao Y, Wagner F, Frank SJ, Kraft AS. (1995). The amino-terminal portion of the JAK2 protein kinase is necessary for binding and phosphorylation of the granulocyte-macrophage colony-stimulating factor receptor beta c chain. J Biol Chem 270:13814-13818.